...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Pfizer seems like a good fit for a BP deal

I can see Resverlogix going under the Shenzhen Hepalink (HL) umbrella should they choose to convert the $ 6 Million Convertable Debenture to equity. That would get them very close to owning 50% of Resverlogix, and if they convert their share purchase warrants to common shares to top up their ownership that gets them to 50%+. They would need to smooth over Eastern and ORI Capital to eliminate any pushback to turn Resverlogix into an affiliate of Shenzhen Hepalink. Fire most of the BODs and Team Members keeping the operation lean and mean. They have the money to conduct BOM2 and go from there. We minions may stand a better chance with HL at the helm as opposed to the uncertainty we're facing. 

Zenith C C can keep on their present path with no interference from Resverlogix. Zenith may stand a better chance of collecting on the Resverlogix Royalty Preferred Shares.

 

Koo (JMO)   

 

 

Share
New Message
Please login to post a reply